NDC 58160-826

HAVRIX

Hepatitis A Vaccine

HAVRIX is a Intramuscular Injection, Suspension in the Vaccine category. It is labeled and distributed by Glaxosmithkline Biologicals Sa. The primary component is Hepatitis A Virus Strain Hm175 Antigen (formaldehyde Inactivated).

Product ID58160-826_2e1feba0-92d3-4d43-974b-3e8a4ef71f00
NDC58160-826
Product TypeVaccine
Proprietary NameHAVRIX
Generic NameHepatitis A Vaccine
Dosage FormInjection, Suspension
Route of AdministrationINTRAMUSCULAR
Marketing Start Date2007-04-13
Marketing CategoryBLA / BLA
Application NumberBLA103475
Labeler NameGlaxoSmithKline Biologicals SA
Substance NameHEPATITIS A VIRUS STRAIN HM175 ANTIGEN (FORMALDEHYDE INACTIVATED)
Active Ingredient Strength1440 [iU]/mL
Pharm ClassesActively Acquired Immunity [PE], Hepatitis A Vaccines [CS], Inactivated Hepatitis A Virus Vaccine [EPC], Vaccines, Inactivated [CS]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 58160-826-52

10 SYRINGE in 1 CARTON (58160-826-52) > 1 mL in 1 SYRINGE (58160-826-43)
Marketing Start Date2007-04-13
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 58160-826-52 [58160082652]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Billing UnitML
Marketing Start Date2011-01-21

NDC 58160-826-32 [58160082632]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Billing UnitML
Marketing Start Date2009-11-21
Marketing End Date2012-02-25

NDC 58160-826-34 [58160082634]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Marketing Start Date2012-02-25
Marketing End Date2020-02-24

NDC 58160-826-05 [58160082605]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Marketing Start Date2012-02-25
Marketing End Date2020-02-24

NDC 58160-826-43 [58160082643]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Billing UnitML
Marketing Start Date2010-08-03

NDC 58160-826-11 [58160082611]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Billing UnitML
Marketing Start Date2007-04-13

NDC 58160-826-41 [58160082641]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Marketing Start Date2007-04-13
Marketing End Date2013-02-08

NDC 58160-826-46 [58160082646]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Marketing Start Date2007-04-13
Marketing End Date2013-02-08

NDC 58160-826-48 [58160082648]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Marketing Start Date2007-04-13
Marketing End Date2013-06-17

NDC 58160-826-01 [58160082601]

HAVRIX INJECTION, SUSPENSION
Marketing CategoryBLA
Application NumberBLA103475
Product TypeVACCINE
Billing UnitML
Marketing Start Date2007-04-13

Drug Details

Active Ingredients

IngredientStrength
HEPATITIS A VIRUS STRAIN HM175 ANTIGEN (FORMALDEHYDE INACTIVATED)1440 [iU]/mL

Pharmacological Class

  • Inactivated Hepatitis A Virus Vaccine [EPC]
  • Actively Acquired Immunity [PE]
  • Hepatitis A Vaccines [CS]
  • Vaccines
  • Inactivated [CS]

NDC Crossover Matching brand name "HAVRIX" or generic name "Hepatitis A Vaccine"

NDCBrand NameGeneric Name
50090-1502HAVRIXHepatitis A Vaccine
55045-3841HAVRIXHepatitis A Vaccine
58160-825HAVRIXHepatitis A Vaccine
58160-826HAVRIXHepatitis A Vaccine
68258-8912HAVRIXHepatitis A Vaccine

Trademark Results [HAVRIX]

Mark Image

Registration | Serial
Company
Trademark
Application Date
HAVRIX
HAVRIX
74042847 1701341 Live/Registered
SmithKline Biologicals, S.A.
1990-03-26

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.